

&lt;!--StartFragment--&gt;RESULT 8

AAR78746

ID AAR78746 standard; peptide; 4 AA.

XX

AC AAR78746;

XX

DT 25-MAR-2003 (revised)

DT 05-OCT-1995 (first entry)

XX

DE Glycosylated haemoglobin immunogenic tetrapeptide.

XX

KW Glycosylated haemoglobin; HbA1c; HbS1c; HbC1c; immunoassay; hapten;

KW immunogen; simultaneous detection; haemoglobinopathy;

KW sickle cell anaemia; diabetes mellitus; disease monitoring.

XX

OS Synthetic.

XX

FH Key Location/Qualifiers

FT Modified-site 1

FT /note= "Fructose-Val"

XX

PN EP598329-A2.

XX

PD 25-MAY-1994

XX

PF 11-NOV-1993; 93EP-00118251.

XX

PR 17-NOV-1992; 92DE-04238705.

PR 31-MAR-1993; 93DE-04310500.

XX

PA (BOEUF) BOEHRINGER MANNHEIM GMBH.

PA (HOFF) ROCHE DIAGNOSTICS GMBH.

XX

PI Karl J., Finke A, Engel W;

XX

DR WPI; 1994-219495/27.

XX

PT New antibodies for simultaneous determin. of different forms of  
PT glycosylated haemoglobin - for diagnosis and monitoring of diabetes and  
PT haemo-globinopathy, e.g. sickle cell anaemia.

XX

PS Claim 1; Page 11; 12pp; German.

XX

CC The present glycosylated oligopeptide is used as an immunogen to generate  
CC antibodies which recognise glycosylated haemoglobin HbA1c and its  
CC variants HbS1c and HbC1c. The new antibodies allow simultaneous detection  
CC of all three forms of haemoglobin. Determination of glycosylated Hb gives  
CC an indication of long-term blood glucose levels for monitoring diabetes  
CC mellitus or haemoglobinopathy such as sickle cell anaemia. (Updated on 25  
CC -MAR-2003 to correct PN field.) (Updated on 25-MAR-2003 to correct PA  
CC field.)

XX

SQ Sequence 4 AA;

Query Match 100.0%; Score 12; DB 2; Length 4;  
Best Local Similarity 100.0%; Pred. No. 2.1e+06;  
Matches 2; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 VH 2

||

Db 1 VH 2

<!--EndFragment-->